Ipilimumab

The combination of pembrolizumab and low-dose ipilimumab appeared tolerable and led to significant antitumor activity among patients with advanced melanoma who previously failed prior immunotherapy, according to phase 2 study results.

A 2-year update on Checkmate9LA suggested that combining nivolumab with ipilimumab and two cycles of chemoradiation may be better than four cycles of chemoradiation alone, according to a speaker at the virtual 2021 ASCO Annual Meeting.

The addition of nivolumab to chemotherapy or ipilimumab significantly improved OS compared with chemotherapy alone among patients with previously untreated advanced esophageal squamous cell carcinoma, according to phase 3 study findings.

A combination of nivolumab and ipilimumab induced significant antitumor activity among men with metastatic castration-resistant prostate cancer and a positive immunogenic signature, according to results of the phase 2 NEPTUNES trial.

Bristol Myers Squibb announced positive results from its phase 3 CheckMate-648 trial of nivolumab for the treatment of patients with unresectable advanced or metastatic esophageal squamous cell carcinoma.

Neoadjuvant combination immunotherapy improved outcomes for patients with operable non-small cell lung cancer, according to results of the randomized phase 2 NEOSTAR trial.

The addition of first-line ipilimumab to pembrolizumab did not improve outcomes for patients with metastatic non-small cell lung cancer who had PD-L1 tumor proportion scores of 50% or greater and no targetable EGFR or ALK aberrations.

A recent study presented at the Gastrointestinal Cancers Symposium revealed low health-related quality of life scores among young adult survivors of colorectal cancer. It was the top story in hematology/oncology last week.

2020 presented many challenges, including the transformation of conferences and meetings into virtual events.

In patients with relapsed or refractory or secondary acute myeloid leukemia/myelodysplastic syndromes, decitabine plus ipilimumab had an expected adverse event profile and showed encouraging clinical activity, according to an ongoing phase 1 study.